Answers are grounded in this paper and cite their sources.
Background: Acute Kidney Injury (AKI) is characterized by rising morbidity and mortality rates, along with significant financial costs associated with its treatment, positioning it as a priority health challenge. Difficult access to accurate biomarkers for renal dysfunction poses challenges in identifying high-risk patients prone to progression to severe AKI. Therefore, this study aimed to identify clinical and laboratory variables that could contribute to future risk stratification approaches in AKI. Methods: This observational retrospective study included 106 patients diagnosed with AKI who were admitted to the emergency department of the HGZ05-IMSS Hospital between January 2020 and July 2023. Multivariate logistic regression was used to identify clinical and laboratory factors associated with in-hospital mortality. Results: Patients with AKI exhibited elevated inflammatory indices (NLR, MLR, and PLR), increased levels of glucose, urea, and C-reactive protein (CRP), and reduced lymphocyte counts, serum albumin, FiO2, and BUN/creatinine (BCR) ratio. The hematological profile showed myeloid predominance, characterized by neutrophilia and lower eosinophil, erythrocyte, and monocyte counts, consistent with systemic inflammation. Multivariable analysis identified COVID-19 infection, thrombocytopenia, low eosinophil levels, and polypharmacy as independent predictors of mortality in AKI patients. Conclusions: These findings underscore the interplay between inflammatory, metabolic, and hematological alterations in AKI and highlight key prognostic factors that may contribute to future risk stratification.
No takes yet. Share an insight, caveat, or question.
Zúñiga-Fernández et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: